Posted 1/2/2024, 3:48:53 PM
Moderna Stock Jumps on Upbeat Sales Outlook and Oppenheimer Upgrade
- Moderna shares jump nearly 14% on Tuesday following Oppenheimer upgrade to "outperform" and CEO reiterating 2025 sales growth target
- Share price fell 45% in 2022, weighing on vaccine sales outlook
- CEO predicts sales growth in 2025 based on RSV vaccine launch in 2024 and potential flu/COVID combo vaccine in 2025
- Oppenheimer forecasts Moderna having 5 products on market by 2026
- CEO maintains break-even target for 2026 as revenue climbs and R&D costs decline